Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod
Open Access
- 3 January 2026
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (2) , 192-201
Abstract
Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning from Gilenya ® to generic fingolimod in people with MS (PwMS). Methods: Retrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya ® and generic fingolimod treatment. Differences in absolute lymphocyte count (ALC) and side effects were also measured by treatment group. Results: The cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya ® was 39.6 years (standard deviation (SD) = 10.6 years), and mean age when starting generic fingolimod was 46.9 years (SD = 11.2 years)). A shorter time to MRI activity ( p = 0.0026) and time to relapse ( p = 0.0027) was observed during generic fingolimod treatment. The ALC increased by 8.81% after generic fingolimod treatment, relative to Gilenya ® (95% CI = (2.00%, 16.08%), p = 0.01), with an intersubject variability of 1.97%. A 2.45-fold increase in side effects was observed with generic fingolimod relative to Gilenya ® (95% CI = (1.38, 4.36), p = 0.002). Conclusion: Measures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.Keywords
This publication has 28 references indexed in Scilit:
- Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisJAMA Neurology, 2025
- Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective studyMultiple Sclerosis and Related Disorders, 2023
- Fingolimod: Assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteriaMultiple Sclerosis and Related Disorders, 2023
- Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated SyndromeJAMA Neurology, 2023
- The consequences of switching from Gilenya® to generics for fingolimodMultiple Sclerosis and Related Disorders, 2023
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated SyndromeAnnals of Neurology, 2022
- Fingolimod Rebound: A Review of the Clinical Experience and Management ConsiderationsNeurology and Therapy, 2019
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodMultiple Sclerosis and Related Disorders, 2018
- Making All Medications Gluten FreeJournal of Pharmaceutical Sciences, 2017
- Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lotsDiagnostic Microbiology and Infectious Disease, 2009